Genetically recombinant mumps virus vaccine (F genotype)

基因重组腮腺炎减毒活疫苗（F基因型）

Report date: 2023/12/26 20:04:01

Base Information

Drug NameGenetically recombinant mumps virus vaccine (F genotype)
Drug Alias NameN/A
ClassificationVaccines > Development/production technology > Live attenuated vaccineVaccines > National Immunization Program > Non-immunization program vaccine(Class II)
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsParotitisMumps
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Saierfusen Biotechnology Co LtdShanghai King-cell Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Saierfusen Biotechnology Co LtdShanghai Qingsai Biotechnology Co LtdShanghai King-cell Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsParotitisMumps
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A